Previous 10 | Next 10 |
Heidelberg, Germany, May 29, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies 2019 Healthcar...
AFMD stock is under heavy selling pressure this morning after Affimed NV (NASDAQ:AFMD) announces the termination of Phase 1 clinical program of AFM11, a CD19/CD3-targeting bispecific T cell engager. AFMD stock Tumbles Germany based biopharmaceutical company Affirmed NV has been one of t...
Affimed N.V. (AFMD) Q1 2019 Earnings Conference Call May 22, 2019 08:30 AM ET Company Participants Gregory Gin - Head, Investor Relations Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Conference Call Partic...
OncoSec Medical (NASDAQ: ONCS ) -31% on pricing equity offering. More news on: OncoSec Medical Incorporated, Ekso Bionics Holdings, Inc., Tocagen Inc., Stocks on the move, Read more ...
Affimed N.V. (NASDAQ: AFMD ) plans to focus its R&D investments on advancing clinical trials for innate cell engager candidates, AFM13 and AFM24 and also provides corporate updates. More news on: Affimed N.V., Healthcare stocks news, Stocks on the move, Read more ...
Affimed (NASDAQ: AFMD ): Q1 GAAP EPS of €0.03. More news on: Affimed N.V., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
- Company to focus on the development of AFM13, AFM24 and preclinical innate cell engagers, decides to terminate AFM11 T cell engager Phase 1 program - - Received milestone payment from Genentech, continuing to strengthen cash position from non-dilutive sources - - Clinical study u...
Heidelberg, Germany, May 16, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it will host a conference call on Wednesday, May 22, 2019 at 8:30 a.m. ET to disc...
Mustang Bio ( MBIO ) - As I write this, shares have risen by over 300% after hours after the company announced that the New England Journal of Medicine had published data from St. Jude Children's Research Hospital regarding an early stage gene therapy trial. Specifically, the Phase 1/2 stud...
Heidelberg, Germany, April 17, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) additional information...
News, Short Squeeze, Breakout and More Instantly...
Affimed N.V. Company Name:
AFMD Stock Symbol:
NASDAQ Market:
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N....
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily p...